RxDoctor Payments DataLook up a doctor →

Michael Hayden, DO

Family Medicine · Cranston, RINPI 1770512766

Payments from drug & device makers

$12,036in general payments, 2019–2025

Across 608 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$948
  • Abbott$753
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$12,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,036 in reported general payments places this provider in the 90th percentile of 222 family medicine providers in Rhode Island.

See all family medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$44,685
Medicare patients
79
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$63,904
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$30,993
JardianceEmpagliflozin39$28,494
EliquisApixaban33$23,193
Breo ElliptaFluticasone/Vilanterol36$22,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$22,301
XareltoRivaroxaban28$15,591
Soliqua 100-33Insulin Glargine/Lixisenatide11$12,369
Atorvastatin Calcium541$7,015
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,208
Albuterol Sulfate HfaAlbuterol Sulfate79$2,714
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide48$2,664
Levemir FlexpenInsulin Detemir16$2,601
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,453
Losartan Potassium229$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,401$63,90453 claims
GSKBreo Ellipta, Trelegy Ellipta$689$45,08954 claims
Boehringer IngelheimJardiance$577$28,49439 claims
PfizerEliquis$1,375$23,19333 claims
Johnson & JohnsonXarelto$948$15,59128 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$709$12,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 family medicine providers in Rhode Island.

Other family medicine in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →